UK-US Pharmaceutical Deal Could Lead to 229,000 Excess Deaths, Study Warns
Research in BMJ highlights potential consequences of diverting NHS funds to US medicines
Quick Look
A UK-US pharmaceutical trade deal may cause 229,000 excess deaths in the UK by 2036 due to diverted NHS funding, according to BMJ research, as billions are allocated to US medicines with no additional NHS funding
AI-generated summary
Why It Matters
The UK-US pharmaceutical trade deal was signed in December, aiming to reduce tariffs and increase access to new medicines
Research published in the British Medical Journal (BMJ) has found that a United Kingdom-United States pharmaceutical deal could cause 229,000 excess deaths as a result of the diversion of billions of pounds away from Britain’s National Health Service (NHS)... (full article text preserved with paragraph breaks)
What to Watch
AI outlook — possibilities, not facts
Increased pressure on the UK government to reassess the deal
Likely · Within months
Open Questions
- Will the UK government conduct a public impact assessment?
- How will the NHS mitigate the predicted health outcomes?
